Sacituzumab Govitecan for Triple-Negative Breast Cancer. Reply.
사설/논평
0/5 보강
APA
Tolaney SM, Schmid P (2026). Sacituzumab Govitecan for Triple-Negative Breast Cancer. Reply.. The New England journal of medicine, 394(15), 1554. https://doi.org/10.1056/NEJMc2602392
MLA
Tolaney SM, et al.. "Sacituzumab Govitecan for Triple-Negative Breast Cancer. Reply.." The New England journal of medicine, vol. 394, no. 15, 2026, pp. 1554.
PMID
41985149 ↗
같은 제1저자의 인용 많은 논문 (5)
- Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
- Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.
- Optimal treatment for metastatic HER2+ breast cancer.
- Understanding first-line treatment patterns and survival outcomes across sociodemographic groups of women with metastatic triple-negative breast cancer in the United States: a real-world study.